Angiotech CEO Says Recap Plan Best Alternative

A plan by Angiotech Pharmaceuticals Inc. to form a new subsidiary and raise up to $300 million in a notes offering to reduce debt is the best alternative in a "horrific" financing environment, the company's chief executive says.
Canadian Business